Experienced in Porphyria

Dr. Joyce Teng

Lpch Medical Group Div Of Lucile
Palo Alto, CA
Experienced
in Porphyria
Specialties:Dermatology | Pediatrics
OverviewInsuranceLocationsClinical Research

Overview

Joyce Teng is a Dermatologist and a Pediatrics provider in Palo Alto, California. Dr. Teng and is rated as an Experienced provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, and Liver Embolization.

Her clinical research consists of co-authoring 101 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Porphyria.

Specialties
Dermatology
Pediatrics
Licenses
Dermatology in CA
Hospital Affiliations
Lucile Salter Packard Children's Hsp At Stanford
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

LPCH MEDICAL GROUP DIV OF LUCILE
725 Welch Rd, Palo Alto, CA 94304
650-498-7200

Additional Areas of Focus

Dr. Teng has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Enrollment Status: Available
Publish Date: October 28, 2024
Intervention Type: Drug
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
Enrollment Status: Completed
Publish Date: September 11, 2023
Intervention Type: Drug
Study Drug: TolaSure
Study Phase: Phase 1
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: VT30
Study Phase: Phase 1/Phase 2
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Drug
Study Drugs: Sirolimus, Vehicle
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: January 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

107 Total Publications

An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma.
An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma.
Journal: bioRxiv : the preprint server for biology
Published: July 19, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Sunil S. Dhawan
Dermatology
Expertise in
21
conditions
Dr. Sunil S. Dhawan
Dermatology

East Bay Dermatology Medical Group Inc.

995 Montague Expy, Suite 111, 
Milpitas, CA 
 (16.0 mi)
408-957-7676
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Offers Telehealth

Sunil Dhawan is a Dermatologist in Milpitas, California. Dr. Dhawan and is rated as an Advanced provider by MediFind in the treatment of Porphyria. His top areas of expertise are Acne, Comedones, Nummular Eczema, and Atopic Dermatitis.

Expertise in
7
conditions
Dr. Shurong Chang
Dermatology
Expertise in
7
conditions
Dr. Shurong Chang
Dermatology

East Bay Dermatology Medical Group Inc.

995 Montague Expy, Suite 111, 
Milpitas, CA 
 (16.0 mi)
408-957-7676
Experience:
14+ years
Languages Spoken:
English, Mandarin

Shurong Chang is a Dermatologist in Milpitas, California. Dr. Chang has been practicing medicine for over 14 years and is rated as an Advanced provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Scabies, Comedones, Plaque Psoriasis, and Psoriasis.

Expertise in
40
conditions
Dr. Amit G. Pandya
Dermatology
Expertise in
40
conditions
Dr. Amit G. Pandya
Dermatology

Sutter Health - Mountain View Center

Mountain View, CA 
 (6.2 mi)
650-934-7676
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amit Pandya is a Dermatologist in Mountain View, California. Dr. Pandya and is rated as an Elite provider by MediFind in the treatment of Porphyria. His top areas of expertise are Hypomelanotic Disorder, Vitiligo, Porphyria Cutanea Tarda, Melasma, and Thrombectomy. Dr. Pandya is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile